Comparing the current results to its competitors, Harmony Biosciences Holdings Inc reported Revenue increase in the 2 quarter 2026 by 30.42 % year on year. The sales growth was above Harmony Biosciences Holdings Inc 's competitors' average revenue growth of 24.5 %, achieved in the same quarter.
Harmony Biosciences Holdings inc Net Income in the 2 quarter 2026 grew year on year by 89.64%, faster than the Harmony Biosciences Holdings Inc 's competitors average income growth of 7.9 %
October 23, 2025
: Harmony Biosciences Holdings, Inc. has announced a strong performance for the third quarter of 2025, primarily propelled by its flagship drug, WAKIX (pitolisant). This article outlines the key developments contributing to the company s growth, insights into strategic patent settlements, and the promising outcomes from their ongoing clinical research.Harmony Biosciences Holdings, Inc., a leading pharmaceutical entity, has reported preliminary results for the third quarter of 2025 that demonstrate robust growth in its primary franchise, WAKIX (pitolisant). Alongside this revenue surge, the company has fortified its intellectual property positions through strategic settlements and presented optimistic researc...
Publicly Traded Peers of Harmony Biosciences Holdings inc
Supernus Pharmaceuticals inc Share Performance
-0.46%
Over The Past 5 Days
Supernus Pharmaceuticals inc
Profile
Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.
Nls Pharmaceutics Ltd is a pharmaceutical company with a business model centered around research, development, and commercialization of innovative drug therapies. They focus on designing and formulating novel drug delivery systems that improve the efficacy and safety of existing medications. Nls Pharmaceutics aims to bring their advanced drug delivery technologies to market by partnering with larger pharmaceutical companies or seeking regulatory approval for their own products.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Cormedix Inc operates on a business model centered around the research, development, and commercialization of innovative pharmaceutical products for the prevention and treatment of infectious and inflammatory diseases. The company focuses on utilizing its expertise in antimicrobial and immunological technology to address unmet medical needs. By leveraging collaborations, partnerships, and regulatory approvals, Cormedix aims to bring its products to market and improve healthcare outcomes for patients.
Sources:
Harmony Biosciences Holdings inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Harmony Biosciences Holdings inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
